Clinical Trials Directory

Trials / Terminated

TerminatedNCT00512538

Apligraf Versus Standard Therapy in the Treatment of Diabetic Foot Ulcers

A Randomized, Open-Label, Multi-Center Study to Compare the Safety and Efficacy of Apligraf Versus Standard Therapy (i.e., Saline Moistened Dressing Regimen) in the Treatment of Diabetic (Primarily Neuropathic) Foot Ulcers

Status
Terminated
Phase
Phase 3
Study type
Interventional
Enrollment
82 (actual)
Sponsor
Organogenesis · Industry
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine the ability of Apligraf to improve the time to and incidence of complete wound closure of diabetic foot ulcers, as compared to diabetic foot ulcers treated with standard therapy.

Detailed description

Ulceration of the diabetic foot is a result of multiple problems including repetitive stress on a neuropathic or insensate area that is often associated with an underlying bony prominence. By healing diabetic foot ulcers quickly the risks of infection, osteomyelitis (infeciton of the bone) and limb loss can be reduced. This study will evaluate the ability of Apligraf to heal diabetic foot ulcers that have been present for at least 2 weeks and are between 1 - 16 cm2 in area. Patients will be randomized to either (50:50 chance) treatment with Apligraf or a saline moistened dressing regimen (standard therapy). All patients will receive standard cares for the ulcers which includes debridement, orthotics and off-loading throughout the treatment period.

Conditions

Interventions

TypeNameDescription
DEVICEBi-layered cell therapy (Apligraf)

Timeline

Start date
2000-10-01
Completion
2002-09-01
First posted
2007-08-07
Last updated
2007-08-07

Source: ClinicalTrials.gov record NCT00512538. Inclusion in this directory is not an endorsement.